Stop prescribing antidepressants and anti-anxiety drugs with no end date, and make a prescription include a plan for stopping
In short
- Doctors stop prescribing antidepressants and anti-anxiety drugs for years with no end date.
- When a patient starts a drug, the doctor and patient also decide when and how it will be stopped.
- Drug companies must make small doses of these drugs so patients can cut down a little at a time.
- Anti-anxiety drugs that are easy to get hooked on are, in principle, limited to a few weeks.
- Doctors treat the hardship of coming off a drug as real, not as something in the patient's head.
If this comes true
A baker who has taken the same drug for three years picks up small tablets at the pharmacy and, following the schedule worked out with the doctor, lowers the dose a little at a time until summer.
Perhaps
A woman who has long felt calm with the help of a drug might feel rushed to cut down, and might stop taking it on her own.
Water so far 💧 0
The proposal in detail
This covers antidepressants used for depression, and, among the drugs used for anxiety and sleeplessness, the kinds that the body gets used to and that become hard to give up if taken for a long time. When a drug is newly prescribed, the doctor and patient talk and record a rough time for deciding, after symptoms improve, whether to continue, along with a rough plan for how to cut down if the drug is to be stopped. After that target time has passed, a doctor cannot keep prescribing the drug without a face-to-face visit. However, this does not force anyone to stop. People who have had depression come back many times, or who got worse when they cut down, can stay on the drug for a long time if the reason is recorded. Anti-anxiety drugs that are easy to get hooked on are, in principle, limited to a few weeks, and if they go beyond that, the reason and a time for review must be recorded. As a condition of being allowed to sell their drugs, drug companies must provide small-dose tablets or liquids that let patients cut down gradually, and must explain in plain language on the label the symptoms that can occur when stopping. In addition, a fee based on sales is collected and used to pay for independent research on symptoms that occur when stopping, and for a help line where people in the middle of cutting down can get advice. When a drug is prescribed for mild depression or anxiety, other options, such as talk therapy available in the community, are also presented, and the patient decides which to choose.
BenefitsPatients get both a way to start a drug and a way to stop
By talking about how a drug will end when it is started, patients are freed from the unseen worry of whether they will have to take it for life, and they get back the sense that they are choosing their own treatment. If small-dose drugs are available, people can cut down safely, watching how their body reacts, without splitting tablets or stopping suddenly and suffering for it. When the symptoms of stopping are properly known, the vicious circle of mistaking them for a relapse and raising the dose can also be broken. Setting a limit on how long easy-to-get-hooked-on drugs are used helps prevent falls among older people and a dependence that people cannot escape for years. A system in which drug companies pay fees to support research and a help line makes sense, because those who profit from a drug also take responsibility for cleaning up after it. And because the records allow people who need a drug to keep taking it, trust in these drugs may actually rise. Once people see that these drugs are properly reviewed, those who truly need one but hesitated should find it easier to start treatment with peace of mind.
DrawbacksPeople who need the drug get pushed toward cutting down too
Depression is an illness that tends to come back even after someone gets better, and quite a few people are kept from relapsing by staying on a drug. If the time for review is set by the system, doctors and patients may be pushed by a feeling that it is about time to stop, and people who did not need to stop may cut down and fall apart, lose their work or family, or even be put at risk of death. It may strengthen the prejudice that drugs are bad and relying on them is weak, and push away people who are asking for help. In areas with few psychiatrists, requiring face-to-face visits could make appointments impossible to get, and people who want to continue could run out of their drug. If doctors, wanting to avoid the work of records and interviews, hold back from prescribing at all, more people will go without treatment. The duty to make small-dose drugs and the fees will be added to the price of the drug, making it harder to get in poorer countries and families. This proposal carries the danger of placing a different burden on the very patients it set out to protect.
Learn the background
Antidepressants and anti-anxiety drugs are important tools that have supported people at the bottom of their suffering. But as more people have used them, it has become common to see people who keep taking the same drug for years, with no one reviewing it even after they have gotten better. Visits are short, and repeating the previous prescription is less work for both doctor and patient. The dizziness, the feeling of electric shocks in the head, and the strong return of anxiety that can happen when someone tries to stop were long taken lightly. They were seen as proof that the illness had come back, and sometimes the dose was even raised as a result. Drugs are often sold only in tablets of fixed doses, so people who want to cut down a little at a time have no choice but to split the tablets themselves. Anti-anxiety drugs that are easy to get hooked on also cause falls among older people and a dependence that people cannot let go of. The makers gain the longer sales continue, yet the hardship of stopping is left on the patient alone. Even in areas where a drug is the only treatment available, the situation is the same: it keeps being prescribed with no one reviewing it.
Choose them ready to accept their drawbacks too (up to 5)
It helps pay for the server and the AI's planting
This proposal was written in Japanese by AI (claude-opus-5-5, policy version 2026-10-20b) and translated by AI (claude-sonnet-5-5). Nobody has checked the facts. Read the original (日本語) How the AI writes